Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
NEUROLOGY OF COVID–19 ; 2021.
Article in English | EuropePMC | ID: covidwho-1824424
2.
Eur Respir J ; 56(4)2020 10.
Article in English | MEDLINE | ID: covidwho-876309
3.
Respiration ; 99(8): 667-677, 2020.
Article in English | MEDLINE | ID: covidwho-695232

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a potentially fatal disease that is of great global public health concern. OBJECTIVE: We explored the clinical management of inpatients with COVID-19 in Italy. METHODS: A self-administered survey was sent by email to Italian physicians caring for adult patients with COVID-19. A panel of experts was selected according to their clinical curricula and their responses were analyzed. RESULTS: A total of 1,215 physicians completed the survey questionnaire (17.4% response rate). Of these, 188 (15.5%) were COVID-19 experts. Chest computed tomography was the most used method to detect and monitor COVID-19 pneumonia. Most of the experts managed acute respiratory failure with CPAP (56.4%), high flow nasal cannula (18.6%), and non-invasive mechanical ventilation (8%), while an intensivist referral for early intubation was requested in 17% of the cases. Hydroxychloroquine was prescribed as an antiviral in 90% of cases, both as monotherapy (11.7%), and combined with protease inhibitors (43.6%) or azithromycin (36.2%). The experts unanimously prescribed low-molecular-weight heparin to patients with severe COVID-19 pneumonia, and half of them (51.6%) used a dose higher than standard. The respiratory burden in patients who survived the acute phase was estimated as relevant in 28.2% of the cases, modest in 39.4%, and negligible in 9%. CONCLUSIONS: In our survey some major topics, such as the role of non-invasive respiratory support and drug treatments, show disagreement between experts, likely reflecting the absence of high-quality evidence studies. Considering the significant respiratory sequelae reported following COVID-19, proper respiratory and physical therapy programs should be promptly made available.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Coronavirus Infections/therapy , Hospitalization , Pneumonia, Viral/therapy , Practice Patterns, Physicians' , Protease Inhibitors/therapeutic use , Respiration, Artificial/methods , Respiratory Insufficiency/therapy , Adult , Aged , Anticoagulants/therapeutic use , Azithromycin/therapeutic use , Betacoronavirus , COVID-19 , Cannula , Cardiology , Continuous Positive Airway Pressure/methods , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Critical Care , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , Intensive Care Units , Internal Medicine , Italy , Lung/diagnostic imaging , Middle Aged , Noninvasive Ventilation/methods , Pandemics , Physicians , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Pulmonary Medicine , Referral and Consultation , Respiratory Insufficiency/etiology , SARS-CoV-2 , Surveys and Questionnaires , Tomography, X-Ray Computed , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL